CRISPR gRNA Nomination
ICHORtec’s Quantum Leap in CRISPR Gene Editing Precision
ΔG-Driven Innovation for the Next Generation of Molecular Science
In the rapidly evolving field of genomic medicine, CRISPR-based gene editing has redefined how we think about treating disease — from repairing defective genes to developing tailored cancer therapies. Despite this promise, the technology continues to face its greatest limitation: uncertain specificity. Off-target mutations, inconsistent editing efficiency, and lengthy design-validation cycles still hinder translation from lab to clinic.
The Breakthrough: ICHORtec’s Quantum FMB® Platform
At ICHORtec, we have introduced a new dimension to molecular precision — Quantum Fluorimetry of Molecular Binding (Quantum FMB®) — that transforms CRISPR design from a trial-and-error process into a predictive, physics-based science.
By directly measuring free energy (ΔG), the universal determinant of molecular binding, the Quantum FMB® platform identifies which guide RNAs (gRNAs) truly bind their DNA targets with optimal affinity and specificity — even down to single-nucleotide differences.
This capability closes the long-standing gap in CRISPR workflows between computational prediction and biological validation.
ΔG-Driven Precision Workflow
Our Three-Stage ΔG-Driven Precision Workflow transforms molecular discovery into a fully predictive, data-driven process — from computational design to preclinical validation. By directly measuring the free energy of nucleic-acid hybridization (ΔG), the platform ensures unmatched precision across the entire molecular value chain.
1. In Silico Design
Advanced computational modeling designs and ranks gRNA candidates based on sequence complementarity, off-target risk, and predicted hybridization energy.
2. In Vitro Screening (ICHORscope)
Using our fluorescence-based ICHORscope assay, shortlisted gRNAs are evaluated for hybridization stability — enabling early elimination of weak candidates and focusing resources on high-performing guides.
3. In-Cell and Preclinical Validation
Final validation occurs within engineered cell models, measuring fluorescence shifts (λmax and Δλ) to confirm hybridization strength and sequence specificity.
This ΔG-driven precision continues into preclinical research, bridging computational prediction, experimental validation, and translational readiness.
The result: functional gRNA validation within days, not weeks — achieving quantum-level precision that eliminates uncertainty before costly animal or clinical phases begin.
Core Benefits
- Speed: Preclinical validation in under one week instead of one month.
- Accuracy: Single-nucleotide resolution with reproducible ΔG quantification.
- Predictability: ΔG measurement correlates binding strength with gene-editing outcome.
- Cost Efficiency: Up to 60% reduction in early-stage development expenses.
- Scalability: Seamless integration into existing CRISPR design and screening pipelines.
Quantum-Validated CRISPR: Redefining Therapeutic Potential
With Quantum FMB®, CRISPR transitions from statistical probability to energetic certainty.
In oncology, ΔG-validated editing enables safer and more effective immune cell reprogramming..
And across all therapeutic fields, it minimizes off-target risks, accelerates IND submissions, and reduces attrition throughout development.
Business Model and Market Integration
ICHORtec positions itself as both a Contract Research Partner and an Asset Deal Factory.
Through Quantum FMB®, pharmaceutical and biotech clients gain rapid access to:
- In-silico to in-vitro gRNA validation as a service (RUO)
- Preclinical-grade asset development for licensing or acquisition
- Joint R&D programs in therapeutic gene editing, oncology, and diagnostics
This model generates recurrent revenue via service contracts, royalties, and licensing, while simultaneously building a pipeline of validated assets ready for co-development or transfer — a foundation for unicorn-level growth potential in the precision biotech sector.
Regulatory Pathway and Next Steps
Quantum FMB® technology and the ICHORscope analytical system are progressing toward ISO 13485 and FDA RUO/IVD validation.
Current collaborations in Europe and the U.S. are establishing reference datasets for preclinical and translational applications in CRISPR verification.
During this phase, all Quantum FMB® systems and gRNA Nomination Services are available as Research Use Only (RUO) products under the ICHORtec Scientific Framework, ensuring data integrity, traceability, and reproducibility.
From Energy to Ethics: The Molecular Responsibility
At ICHORtec, we view the ability to measure molecular free energy not merely as a technological milestone, but as an ethical obligation.
When precision becomes measurable, inaction becomes indefensible.
Our mission is to make energetic truth — ΔG itself — the foundation of tomorrow’s medicine, ensuring that every therapeutic decision is based on measurable, reproducible molecular certainty.
